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Abstract
Act1 is an essential adaptor molecule in IL-17-mediated signaling and is recruited to the IL-17
receptor upon IL-17 stimulation. Here, we report that Act1 is a client protein of the molecular
chaperone, Hsp90. The Act1 variant (D10N) linked to psoriasis susceptibility is defective in its
interaction with Hsp90, resulting in a global loss of Act1 function. Act1-/- mice modeled the
mechanistic link between Act1 loss of function and psoriasis susceptibility. Although Act1 is
necessary for IL-17-mediated inflammation, Act1-/- mice exhibited a hyper TH17 response and
developed spontaneous IL-22-dependent skin inflammation. In the absence of IL-17-signaling,
IL-22 is the main contributor to skin inflammation, providing a molecular mechanism for the
association of Act1 (D10N) with psoriasis susceptibility.
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INTRODUCTION
Psoriasis is a chronic inflammatory disease of the skin, which affects approximately 2% of
the general population. Defining histological features of psoriatic skin lesions include
epidermal hyperplasia, with aberrant differentiation and hyperproliferation of keratinocytes,
as well as marked infiltration of leukocytes into the dermis1, 2. Although psoriasis was
initially classified as a TH1-mediated disease, recent studies have highlighted a role for
TH17 cells and their cytokine network in propagating and amplifying skin inflammation3.
TH17 cells are a population of proinflammatory CD4+ effector T cells that are distinct from
TH1 and TH2 cells due to their ability to produce IL-17A, IL-17F, IL-21 and IL-224-7, all of
which are elevated in psoriatic lesions8-10.
While IL-17 is required for host defense against extracellular microorganisms11, 12, it is also
a critical mediator of the pro-inflammatory processes in various autoimmune and
inflammatory disorders. The IL-17-signaling cascade requires a key signaling molecule,
Act1 (Traf3ip2/CIKS), to propagate downstream signaling events13-15. Upon IL-17
stimulation, Act1 is recruited to the IL-17R through a SEFIR-SEFIR-dependent interaction,
exerting K63-linked polyubiquitination of TRAF6 followed by the activation of TAK1 and
the IKK complex, resulting in NF-κB activation16, 17. The absence of Act1 leads to
resistance to IL-17A-mediated inflammation in murine models of experimental autoimmune
encephalomyelitis (EAE) and asthma14, 18, 19. Although Act1 is necessary for IL-17-
mediated inflammatory responses, Act1-/- mice developed spontaneous autoimmune
diseases, including skin inflammation20, which was also seen in mice with a spontaneous
point mutation that introduced an early stop codon in the Act1 gene21. Notably, three
independent genome-wide association studies (GWAS) recently linked a genetic variance of
Act1—Act1 (D10N)—to psoriasis susceptibility22-24. However, important questions
regarding the impact of this variant on the function of Act1 and how this variant might
predispose patients to psoriasis remain unanswered.
One important goal of this study was to investigate the effects of the D10N mutation on
Act1 function. One possibility is that Act1 (D10N) might somehow enhance IL-17 signaling
and IL-17-dependent effector function in skin inflammation. However, we found the
contrary: Act1 (D10N) was unable to interact with any of the known signaling components
in the IL-17 pathway (including IL-17R, TRAFs and IKKi25, 26) and resulted in abolished
IL-17-dependent gene expression. Here we showed that the N-terminus of Act1 contains a
highly conserved region necessary for Act1’s interaction with the molecular chaperone,
Hsp90. Hsp90 is one of the most abundant cellular chaperone proteins and plays a crucial
role in regulating a wide array of proteins essential for cell homeostasis27, 28. Mutations that
affect the N-terminus of Act1, like D10N, led to the loss of regulation by Hsp90 and
consequently, a dead Act1 protein that is unable to propagate IL-17-mediated responses.
Using our Act1-/- mice as a model for this dead mutation, we found that the spontaneous
skin inflammation was the result of the hyper TH17 response in Act1-/- mice, suggesting
immune dysregulation in the absence of a functional Act1. In the absence of IL-17-
signaling, IL-22 appeared to be the main contributor of skin inflammation, as neutralization
of IL-22 resulted in alleviation of the skin phenotype in the Act1-/- mice. Furthermore, we
demonstrated that the hyper TH17 response is T cell-intrinsic, since T-cell-specific Act1-/-
mice also developed a hyper TH17 response. Consistent with this, Act1-/- T cells transduced
with Act1 (D10N) exhibited a hyper TH17 response compared to Act1-/- T cells that were
transduced with Act1 (WT), indicating that the nonfunctional Act1 (D10N) is associated
with the dysregulation of T cell function.
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RESULTS
Act1 is a client protein of Hsp90
To search for novel Act1-interacting proteins, lysates from HeLa cells and MEFs (mouse
embryonic fibroblasts) treated with IL-17 were immunoprecipitated for Act1 followed by
Mass Spectrometry (Mass Spec) analysis. One protein in particular, heat-shock protein 90
(Hsp90), was repeatedly detected by Mass Spec as an IL-17-induced, Act1-interacting
protein. We confirmed the interaction by co-immunoprecipitation experiments and found
that Act1 indeed interacted with Hsp90 and IL-17 stimulation further promoted the
interaction (Fig. 1a).
Hsp90 is an ATPase that facilitates the folding and assembly of its “client proteins”29-34.
Loss of Hsp90 chaperone activity results in misfolding of client proteins, leading to their
degradation29-31. As such, Hsp90 inhibitors were used in this study to determine Act1’s
potential as an Hsp90 client protein. Hsp90 inhibitors such as geldanamycin (GA), a
naturally Hsp90 inhibitor, binds to the ATP binding pocket at the N-terminus of Hsp90 to
inhibit ATP binding and ATP-dependent Hsp90 chaperone function31. 17-N-Allylamino-17-
demethoxygeldanamycin (17-AAG), a synthetic derivative of GA, and PU-H71, a purine
scaffold Hsp90 inhibitor, inhibit Hsp90 through similar mechanisms as GA30, 34.
Using Hsp90 inhibitors (17-AAG, and PU-H71), we found a time-dependent reduction in
Act1 protein amounts in MEFs and Hela cells (Fig. 1b and data not shown). Using
cycloheximide (CHX) to block new protein translation, we found that GA accelerated Act1
protein decay suggesting that Act1 protein stability is dependent on Hsp90 (Fig. 1c). In
addition, use of the proteasome inhibitor, MG132, blocked PU-H71–induced decay of Act1
suggesting that the degradation of Act1 upon Hsp90 inhibition occurs through the
proteasome (Fig. 1d). Consistent with reports suggesting that Hsp90 inhibitors lead to the
dissociation of Hsp90 with its client proteins34, we found that after treatment with PU-H71,
Act1 dissociates with Hsp90 in a short time period (Fig. 1e). Taken together, these results
demonstrate that Act1 is a client protein of Hsp90.
Hsp90 activity is required for IL-17- signaling
Because Act1 is essential in IL-17-dependent signaling in autoimmune and inflammatory
diseases14, 15, 18, 19, we sought to determine whether Hsp90 inhibition could interfere with
IL-17 signaling and IL-17-dependent gene expression. MEFs were pretreated with Hsp90
inhibitors for 1 hour to disrupt the interaction of Act1 with Hsp90 (with indiscernible Act1
degradation), followed by IL-17 stimulation. In the presence of the inhibitors, IL-17-
dependent phosphorylation of IκBα, Erk and Jnk were nearly abolished (Fig. 2a-b). Upon
IL-17 stimulation, Act1 modifications (such as phosphorylation) help to govern specificity
for downstream events35, 36. IL-17-induced modification of Act1 was greatly attenuated by
Hsp90 inhibitors, indicating that Act1 is no longer recognized as a substrate of upstream
kinases like IKKi. (Fig. 2a-b, arrow). Consistent with IL-17-induced signaling, IL-17
(IL-17A and IL-17F)-induced gene expression was greatly reduced after treatment with PU-
H71 (Fig. 2c-d). To understand how the Hsp90 inhibitors blocked IL-17 signaling, we
examined the impact of the inhibitors on IL-17-mediated interaction of Act1 with other
signaling components in the IL-17 pathway. Pre-treatment with PU-H71 abolished the
IL-17-dependent interaction of Act1 with TRAF6, TRAF3, TRAF2 and IKKi, as it also
disrupted the interaction between Act1 and Hsp90 (Fig. 2e). These results suggest that
Hsp90 activity plays an essential role in the integrity of Act1 function. Inhibition of Hsp90
chaperone function disrupts the interaction of Act1 with Hsp90 and with other IL-17
signaling molecules, resulting in the loss of IL-17-induced signaling and gene expression.
Wang et al. Page 3
Nat Immunol. Author manuscript; available in PMC 2013 July 01.
$watermark-text
$watermark-text
$watermark-text
The main function of IL-17-induced Act1-mediated signaling is to coordinate local tissue
inflammation via the up-regulation of pro-inflammatory and neutrophil-mobilizing
cytokines and chemokines. We next examined the impact of Hsp90 inhibition on IL-17-
induced pulmonary inflammation in vivo. Wild-type mice were pretreated with DMSO or
PU-H71 for two days prior to intranasal injection with recombinant IL-17. Twenty-four
hours after IL-17 challenge, the mice were analyzed for Bronchoalveolar lavage (BAL) cells
and lung inflammation. Infiltrating cells, like neutrophils, were significantly reduced in
IL-17-challenged PU-H71-pretreated mice compared to IL-17-challenged DMSO-pretreated
mice (Supplementary Fig. 1a). The decreased inflammatory phenotype correlated with
decreased concentrations of CXCL1 (a potent neutrophil-recruiting chemokine) in the BAL
and decreased Cxcl1 expression in the lungs (Supplementary Fig. 1b-c). Furthermore, IL-17-
induced expression of Csf2 and Il6 were also abolished in the lungs of IL-17-challenged,
PU-H71-pretreated mice compared to IL-17-challenged, DMSO-pretreated mice
(Supplementary Fig. 1b). These results indicate the importance of Hsp90 function in IL-17-
induced pulmonary inflammation.
Act1 N-terminus interacts with Hsp90
To determine the region(s) that is required for Act1 to interact with Hsp90, wild-type (WT)
and truncation mutants of Act1 were transfected into HEK293 cells, followed by
immunoprecipitation and immunoblot analysis. The deletion analysis showed that the
deletion of amino acids 1-50 of Act1 resulted in a loss of interaction with Hsp90 (Fig. 3a).
These results indicate that the N-terminus of Act1 is required for the interaction with Hsp90
(Fig. 3b). To further determine the minimum region that is sufficient for interaction with
Hsp90, we transfected HEK293 cells with constructs coding for partial regions of Act1
(Supplementary Fig. 2). Our data indicates that the region between 1-100 amino acids of
Act1 is sufficient for the interaction with Hsp90 (Supplementary Fig. 2). These findings
suggest that the N-terminus of Act1 is necessary and sufficient for the interaction with
Hsp90.
Act1 (D10N) fails to interact with Hsp90
The N-terminus of Act1 consists of a highly conserved motif (Fig. 3c). Recent GWAS
identified a psoriasis susceptibility locus at Act1 (Traf3ip2), including a coding variant of
Act1 altering Aspartic acid at position 10 to Asparagine (D10N, rs33980500) as the most
significant associated SNP (p=1.13×10-20, odds ratio=1.95)24 (Fig. 3c). Since this Act1
variant (D10N) is located within the N-terminus of Act1, we tested the impact of the point
mutation on the interaction of Act1 with Hsp90. WT and Act1 (D10N) were transfected into
HEK293 cells, followed by immunoprecipitation and immunoblot analysis (Fig. 3d). Indeed,
Act1 (D10N) was unable to interact with Hsp90, suggesting that the Aspartic acid at position
10 plays an essential role in the interaction of Act1 with Hsp90.
It has been suggested that Act1 (D10N) is mainly defective in its binding with TRAF624.
We thus explored whether the interaction of Act1 with Hsp90 is TRAF6-dependent. We
have previously identified two putative TRAF binding sites in Act1 (residues 38-42 [TB1]
and 333-337 [TB2])17 (Fig. 4a). Mutation of both TB1 and TB2 (TB12) sites resulted in a
complete loss of interaction between Act1 and TRAF2 and TRAF6 but has no effect on the
interaction of Act1 with Hsp90 (Fig. 4b). Furthermore, when WT and Traf6-/- MEFs were
treated with IL-17, followed by co-immunoprecipitation and immunoblot analysis, we found
that Act1 from both WT and Traf6-/- MEFs were able to interact with Hsp90, indicating that
the IL-17-induced Hsp90 interaction is TRAF6-independent (Fig. 4c).
It is important to point out that Hsp90 functions as part of a chaperone machinery to guide
client protein maturation or degradation in two main forms of Hsp90 complexes. While an
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Hsp90-cdc37-p23 complex stabilizes the client protein, an Hsp90-Hsp70-HOP complex
targets it for proteasomal degradation34. Since the progression of the Hsp90 complex
towards the stabilizing form requires the binding and hydrolysis of ATP, Hsp90 inhibitors
such as PU-H71, tend to drive the complex towards the proteasome-targeting form, leading
to increased proteasomal degradation of the client29. Interestingly, heat-shock protein 70
(Hsp70) was also repeatedly detected by Mass Spectrometry as an IL-17-induced, Act1-
interacting protein, suggesting that Act1 may interact with the whole chaperone machinery
in addition to Hsp90. Therefore, we decided to examine the interaction of Act1 (WT), Act1
(D10N), and Act1 (TB12) with co-chaperone proteins. While IL-17 induced the interaction
of Act1 (WT) and Act1 (TB12) with Hsp70, HOP and p23, there was no detectable
interaction of Act1 (D10N) with these co-chaperone proteins in response to IL-17
stimulation (Fig. 4e). Consistent with these observations, PU-H71 treatment led to the
degradation of Act1 (WT) and Act1 (TB12), but Act1 (D10N) remained unaffected by the
treatment (Fig. 4d). We then examined the impact of PU-H71 on the interaction of Act1 with
co-chaperone proteins. As expected, PU-H71 enhanced the interaction of Act1 (WT) and
Act1 (TB12) with Hsp70 and HOP, but decreased the interaction with Hsp90 and p23 (Fig.
4f). However, Act1 (D10N) still failed to show interaction with the chaperone proteins in the
presence of PU-H71 (Fig. 4f). These observations indicate that the D10N mutation fails to
interact with Hsp90 co-chaperone proteins, which renders this Act1 variant resistant to
Hsp90-dependent regulation.
Act1 (D10N) is a loss of function variant
Because the D10N mutation resulted in the loss of interaction with Hsp90, we examined the
impact of the mutation on IL-17 signaling. We reconstituted Act1-/- MEFs with Act1 (WT),
Act1 (D10N), or vector DNA (Fig. 5a). Re-expression of (WT) but not Act1 (D10N) in
Act1-/- MEFs promoted IL-17-induced phosphorylation of Jnk and Erk as well as activation
of NF-κB (shown by phosphorylation of IκBα, NF-κB DNA binding, and NF-κB-
dependent luciferase activity, Fig. 5b-d). While IL-17 induced the interaction of Act1 (WT)
with IL-17R, TRAFs (2, 3 and 6) and IKKi, there was no detectable interaction of Act1
(D10N) with these proteins in response to IL-17 stimulation (Fig. 5e), suggesting the
inability of Act1 (D10N) to interact with all of its known interacting proteins in the IL-17-
signaling cascade. Interestingly, the Act1 (D10N) mutation also abolished the interaction of
Act1 with CD40 and BAFFR (Supplementary Fig. 3 and data not shown). Previously, a
report suggested that the N-terminus of Act1 contains a novel TRAF6-binding motif
(PVEVDE at amino acids 6-1137). Mutation at this putative TRAF6 binding site (PVEVDE
was mutated to PVAVAA, Act1 T6BM) abolished the interaction of Act1 (T6BM) with
TRAF6. We found that this mutation exhibited the same mechanism of loss of function as
that of D10N (Supplementary Fig. 4): impaired interaction with Hsp90 and with the
signaling components in the IL-17 pathway.
Act1 (D10N) is clearly distinct from Act1 (TB12) since Act1 (TB12), but not Act1 (D10N),
still retained the interaction with Hsp90, TRAF3 and IKKi (Fig. 4b and 5e). Moreover, in
contrast to Act1 (D10N), IL-17 stimulation was able to induce modification on Act1 (TB12)
at similar amounts to that of Act1 (WT) (Fig. 4b, arrow). Although Act1 (D10N) protein
was expressed at a comparable level to Act1 (WT), IL-17 failed to induce modifications on
Act1 (D10N) (Fig. 5d, arrow), an observation seen earlier with Hsp90 inhibition (Fig. 2a-b).
Consistent with these observations, IL-17 (A and F) and IL-17 plus TNF induced expression
of Il6, Cxcl1 and Csf2 were restored in Act1-/- MEFs reconstituted with Act1 (WT), but not
in Act1-/- MEFs reconstituted with Act1 (D10N) (Fig. 5f). IL-17-induced gene expression
was only partially lost in the TB12 mutant cells (Fig. 5f). These results suggest that while
TB1 and TB2 are specific for TRAF6 binding and TRAF6-dependent IL-17 signaling, the
D10N mutation probably perturbed the function of the N-terminal region of Act1 critical for
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the binding with Hsp90, resulting in the loss of a broader function of Act1 than TRAF6-
binding. Furthermore, IL-17-mediated mRNA stability could not be restored in MEFs
reconstituted with Act1 (D10N), whereas it was restored in MEFs reconstituted with Act1
(WT) (Supplementary Fig. 5). Collectively, these observations implicate that the D10N
mutation might have caused a major conformational change in Act1 due to the absence of
appropriate folding by Hsp90, resulting in the inability of Act1 (D10N) to respond to and
propagate IL-17-signaling events.
IL-22-mediated skin inflammation in Act1-/- mice
Our results indicate that the loss of function of Act1 (D10N) is due to the impaired
regulation of Act1 by Hsp90. Given that IL-17A is strongly linked to the pathogenesis of
psoriasis, it is puzzling that a loss-of-function Act1 variant is associated with psoriasis
susceptibility. Although Act1-/- mice are resistant to IL-17-dependent inflammation, such as
EAE, we have previously reported that Act1-/- mice develop spontaneous autoimmune
phenotypes, including skin inflammation20, characterized by epidermal hyperplasia and cell
infiltration. Immunostaining showed that there were substantially more CD3+, CD4+,
CD11b+ and Gr-1+ infiltrating cells in the Act1-/- skin tissue than there were in the controls,
indicating the participation of T cells, macrophages and neutrophils in the skin inflammation
(Fig. 6a). Furthermore, more IL-17+ and IL-22+ CD4+ T cells were detected in the spleen
and lymph nodes of Act1-/- mice compared to controls (Fig. 6b and Supplementary Fig. 6),
and TH17 cytokine transcripts (Il17a, Il17f, and Il22) were increased in the skin of Act1-/-
mice (Fig. 6d). Cytokine production by skin infiltrates isolated from Act1-/- mice also
indicated elevated IL-17A and IL-22 production compared to skin infiltrates isolated from
the control mice, whereas IL-4, IL-6, TNF, and IL-21 were undetectable (Figure 6c).
Surprisingly, IL-21 transcripts were undetectable in the lymph nodes or the skin of Act1-/-
mice. These results suggest that Act1 deficiency led to a hyper TH17 response with a bias
towards IL-17-IL-22 expression evident in the periphery (spleen and LNs) as well as in the
skin.
Given that IL-17A/F signaling is abrogated in Act1-/- mice, and IL-21 is undetectable, we
hypothesized that IL-22 is the major contributor to skin inflammation. To test this
hypothesis, we neutralized Act1-/- mice with anti-IL-22 neutralizing antibody followed by
histopathology analysis. Treatment with anti-IL-22 neutralizing antibody reduced epidermal
hyperplasia and inflammatory cell infiltration in the skin of Act1-/- mice (Fig. 6e).
Consistent with histopathology analysis, anti-IL-22 neutralizing antibody substantially
reduced the expression of Il17a, Il17f, Il22 and Il23 in the skin of Act1-/- mice (Fig.6f).
Since immune cells do not express the IL-22 receptor, IL-22 likely contributes to the
inflammatory disease process through keratinocytes by inducing the expression of anti-
microbial peptides and cytokines that amplify and maintain the pro-inflammatory
environment necessary to sustain TH17 cells. Consistent with the literature38, 39, IL-22 was
able to induce the expression of Il8, Defb1, S100a8, S100a9 and in human keratinocytes
(Supplementary Fig. 7). We indeed observed that neutralizing IL-22 substantially reduced
the expression of Cxcl1, S100a8, S100a9 and Defb1 in the skin of Act1-/- mice (Fig. 6f).
Taken together, these results suggest that the TH17-derived cytokine, IL-22, plays a critical
role in the skin inflammation in Act1-/- mice.
Like the Act1-/- mice, where the IL-17 signaling is abrogated, the Il17rc-/- mice also
exhibited a hyper TH17 response. Increased TH17 cells were detected in the spleen and
lymph nodes of Il17rc-/- mice compared to controls (Supplementary Fig. 8a and data not
shown). Previous EAE experiments have shown that T cells from Il17rc-/- mice had higher
antigen-specific TH17 cell response upon MOG33-55 immunization than wild-type
controls40. Il17rc-/- mice also developed skin inflammation depicted by epidermal
hyperplasia and T cell infiltration (Supplementary Fig. 8b). Consistent with the
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histopathology analysis, we observed increased expression of Il17a, Il17f, Il22, S100a8,
S100a9 and Defb1 in the skin of Il17rc-/- mice (Supplementary Fig. 8c). We also detected
elevated TH17 cytokines, IL-17A and IL-22, produced by skin infiltrating cells from Il17rc-/-
mice compared to littermate controls (Supplementary Fig. 8d). These results suggest that the
impairment of IL-17-induced Act1-mediated signaling resulted in increased TH17 cells and
IL-22-dependent skin inflammation in Act1-/- mice. Indeed, neutralization of IL-22 in
Il17rc-/- mice alleviated the inflammatory skin phenotype (Supplementary Fig. 8e-f).
Act1 D10N T cells exhibit hyper TH17 response
To eliminate the hyper TH17 response in Act1-/- mice, we generated Act1-/- Il23r-/- mice
because it is well known that IL-23 plays a critical role in TH17 cell maintenance and
expansion4, 6. TH17 cells and cytokine transcripts (including IL-22) were indeed reduced in
the lymph nodes and the skin of Act1-/- Il23r-/- mice compared to Act1-/- mice (Fig. 7a and
Supplementary Fig. 9a). Histopathology analysis showed that epidermal hyperplasia and T
cell infiltration were also decreased in the skin of Act1-/- Il23r-/- mice, supporting the critical
role of TH17 cells in the skin inflammation of Act1-/- mice (Fig. 7b). Consistent with
histopathology analysis, we observed decreased expression of TH17 cytokines (Il17a, Il17f
and Il22), S100a8, S100a9 and Defb1 in the skin of Act1-/- Il23r-/- mice compared to Act1-/-
mice (Fig. 7c). A previous study reported a spontaneous point mutation that introduced a
premature stop codon in Act1 led to spontaneous skin inflammation with elevated TH17
cytokine transcripts in the mutant mice21. Like this study, we have previously observed
hyper IgE production in our Act1-/- mice attributed to the loss of negative regulation in B
cells20. We now found that this hyper IgE can also be reversed in the Act1-/- Il23r-/- mice
(Supplementary Fig. 9b), suggesting a link between the hyper TH17 response and the hyper
IgE production in these mice.
Next, we sought to determine the cell type that is responsible for the hyper TH17 response.
Using T cell-specific Act1-deficient mice (Lck-Cre+ Act1fl/-), we examined the T cell
contribution to this phenotype. We also observed skin inflammation along with CD4+,
CD8+, and CD11b+ infiltrates in the skin of Lck-Cre+ Act1fl/- mice whereas it was not
observed in littermate controls (Fig. 8a). Furthermore, skin infiltrates isolated from Lck-
Cre+Act1fl/- mice produced more IL-17A and IL-22 than skin infiltrates from control mice
(Fig. 8b). When naïve T cells were polarized to TH17 cells ex vivo, Lck-Cre+ Act1fl/- T cells
showed more IL-17+ CD4+ T cells than controls, implicating the critical role of Act1 in
modulating TH17 polarization (Fig. 8c). Consistent with this, we detected more Il17a and
Il22 expression in the Lck-Cre+ Act1fl/- TH17 cells and more IL-17 and IL-22 in the culture
supernatant of Lck-Cre+ Act1fl/- TH17 cells than the controls (Fig. 8d). To determine
whether the D10N mutation in T cells was sufficient for the hyper TH17 response, we
transduced Act1-/- T cells with retrovirus carrying vector, Act1 (WT), or Act1 (D10N) and
polarized the T cells under TH17 skewing conditions. GFP+ cells were sorted for RT-PCR
analysis of Il17a and Il22 expression. The Act1-/- T cells transduced with Act1 (D10N)
exhibit a hyper TH17 response compared to Act1-/- T cells that were transduced with Act1
(WT) (Fig. 8e). Furthermore, when we injected Act1-/- T cells transduced with retrovirus
carrying vector, Act1 (WT), or Act1 (D10N) into RAG1-/- mice and examined the lymph
nodes and spleens two weeks later, we observed that Act1 (D10N) conferred a hyper TH17
response (Fig. 8f-g). Taken together, these results suggest that the nonfunctional Act1
(D10N) is associated with the dysregulation of T cell function.
DISCUSSION
In this study, we found that although Act1 is necessary for IL-17-mediated inflammatory
responses, Act1-/- mice exhibited a hyper TH17 response and developed spontaneous skin
inflammation, which was attenuated by IL-22 neutralization. These results demonstrate that,
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in the absence of IL-17-Act1 signaling, the consequent hyper TH17 response is IL-22 biased,
which acts as the main contributor of skin inflammation. Considering the critical role of
IL-22 in human psoriasis, this mouse model provides a plausible interpretation for how the
Act1 variant (D10N) is linked to psoriasis susceptibility. We found that Act1 is a client
protein of the molecular chaperone, Hsp90. The Act1 variant (D10N) is defective in its
interaction with Hsp90, resulting in a complete loss of function of Act1. Importantly, Act1-/-
T cells restored with the D10N variant, but not the wild-type Act1, showed a hyper TH17
phenotype, demonstrating that the nonfunctional Act1 is associated with a dysregulation of
T cell function, a risk factor for autoimmune diseases including psoriasis1, 2, 41.
The Act1 D10N mutation is within the highly conserved motif at the N-terminus of Act1,
which contains an Hsp90-binding region that when altered, as in Act1 (D10N) and Act1
(T6BM), leads to a broad loss of function of Act1 and consequently, defective IL-17A-
signaling. The loss of Act1 modifications during Hsp90 inhibitor use indicates that the
chaperone activity of Hsp90—and thus, the proper folding of Act1—is critical for Act1 to be
recruited to the receptor complex and to be recognized as a substrate of upstream kinases
during IL-17 signaling. Mutations that affect Act1’s ability to bind to Hsp90—like Act1
(D10N) and Act1 (T6BM)—most likely resulted in major structural and conformational
changes in Act1 that abolished IL-17-mediated signaling. Interestingly, we also observed
that the interaction between Act1 and Hsp90 could be enhanced by IL-17A stimulation,
which suggests that in addition to its chaperone function, Hsp90 may act as a scaffolding
protein in the IL-17A signaling pathway. Further evaluation would be necessary to decipher
the possible role of Hsp90 in the signaling cascade.
Because IL-17A is strongly linked to the pathogenesis of psoriasis, it appears contradictory
that the loss of function of Act1 (D10N) and consequent impaired IL-17 signaling are linked
to increased susceptibility for psoriasis. Since the D10N mutation renders Act1
nonfunctional, we attempted to use the Act1-/- mice to model the in vivo impact of this dead
mutation. Interestingly, although Act1-/- mice are defective in IL-17-mediated signaling,
IL-22 functions as the major player in the pathogenesis of skin inflammation in Act1-/- mice.
In the normal state, IL-22 acts as a skin repair agent to induce keratinocyte proliferation and
maintain barrier integrity. In the pathogenic state, elevated and dysregulated IL-22
production leads to keratinocyte hyperproliferation and aberrant differentiation8. In murine
models of psoriasis, including data shown in this report, skin inflammation can be attenuated
by IL-22 neutralization42-44. Elevated IL-22 protein and gene transcripts are also found in
the serum and skin lesions of patients with psoriasis9. It is possible that in patients with
psoriasis who carry the Act1 variant(s), the pathogenesis of the disease is mediated by IL-22
compensating for the loss of IL-17 signaling. Thus, these findings may provide an
individualized therapeutic approach for patients carrying the Act1 variant. Currently, no
animal model has been able to mimic all of the characteristics of human psoriasis. However,
given the genetic association of Act1 (D10N) to psoriasis susceptibility in humans, our
findings of complete loss of function of Act1 (D10N) and the skin inflammation in Act1-/-
mice underscore a possible mechanistic link between the skin inflammation in Act1-/- mice
and the pathogenesis of psoriasis in patients with the Act1 variant.
Intriguingly, in an IL-23-induced skin inflammation model of psoriasis, IL-23 injection led
to more IL-22 gene transcripts in the skin of the Il17a-/- mice than in control mice45. Taken
together, these findings suggest that the loss of IL-17 signaling may result in a hyper TH17
response, implicating a negative regulatory role of IL-17 signaling in TH17 cell polarization
in vivo. Future studies are required to understand the detailed molecular mechanism for how
IL-17 signaling may modulate the TH17 cell response. It is important to point out that even
though there is an increase in the TH17 cell population, Il17rc-/- and Act1-/- mice remain
resistant to IL-17-dependent pathogenesis like experimental autoimmune encephalomyelitis
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(EAE)14, 18, 40. These published data and the results presented in this study collectively
suggest that TH17-mediated diseases are cytokine-specific. While IL-17 plays a dominant
role in TH17-mediated EAE, IL-22 is responsible for the TH17-mediated skin inflammation
in Act1-/- and Il17rc-/- mice.
We demonstrated that the hyper TH17 response in Act1-/- mice is T cell-intrinsic since skin
inflammation and hyper TH17 response were also observed in Lck-Cre+ Act1fl/- mice.
Furthermore, Act1-/- T cells reconstituted with Act1 (D10N) exhibited a hyper TH17
response while cells reconstituted with wild-type Act1 did not, indicating that the Act1
D10N mutation and its loss of function was sufficient to cause the hyper TH17 phenotype.
Our data from the Il17rc-/- mice indicate a possible negative feedback of IL-17 signaling on
TH17 cells. However, since Act1 also functions under signaling mediated by the other IL-17
family members, it would thus be important to determine whether T cell-specific Il17rc-/-
mice also exhibit a hyper TH17 response in the future.
The increase in TH17 cells, cytokine transcripts, and skin inflammation in Act1-/- mice was
reversed in Act1-/- Il23r-/- mice, further supporting the critical role of TH17 cells in the skin
inflammation of Act1-/- mice. We also found that the hyper IgE level in Act1-/- mice can be
reversed in Act1-/- Il23r-/- mice, suggesting a causal link between the hyper TH17 response
and the hyper IgE production in these mice. Although serum IgE concentrations are not
among the common diagnostic tests for psoriasis, nor have serum IgE concentrations been
well-documented in patients with psoriasis, elevated IgE have been reported in a cohort of
patients with psoriatic erythroderma (PE), a severe type of psoriasis46. Serum IgE
concentrations were elevated in 81.3% of the PE group, compared to 6.3% of the control
group. In addition, case studies involving psoriasiform lesions and elevated IgE
concentrations have been similarly documented47, 48. It would thus be interesting to study
the IgE concentrationss in patients carrying the Act1 (D10N) variant to determine whether
this mutation defines a specific cohort of patients with psoriasis.
In addition to Act1’s role as a component in the IL-17R-signaling cascade in fibroblasts,
endothelial cells, epithelial cells, astrocytes, and macrophages, Act1 plays a negative role in
the CD40–CD40L and BAFF–BAFFR signaling pathways in B cells to control B cell
maturation and survival, respectively20. The loss of Act1 thus results in increased numbers
of B cells, which culminates in splenomegaly, lymphadenopathy, hypergammaglobulinemia,
and autoantibody production. The Act1 (D10N) mutation also abolished the interaction of
Act1 with CD40 and BAFFR. Therefore, it is possible that the loss of negative regulation of
B cell function in Act1-/- mice might also contribute to the pathogenesis of the skin
inflammation in mice and possibly in patients with the D10N mutation. However, we found
that Act1-/- μ-/- mice still developed antigen-specific hyper TH17 cell response upon
MOG33-55 immunization and had increased TH17 cells in their spleen and lymph nodes
compared to μ-/- mice, suggesting that the hyper TH17 response in the Act1-/- mice is most
likely independent of B cells (unpublished data, X.L). Nevertheless, it would be interesting
to determine whether patients with psoriasis who carry the Act1 variant have other
autoimmune co-morbidities.
MATERIAL and METHODS
Mice
Act1-/- mice were generated as described previously20. Il23r-/- mice were generated as
described49 and bred to Act1-/- mice to generate Act1-/- Il23r-/- mice. Lck-Cre+ Act1fl/- mice
were generated as previously described50. Littermate controls were used as WT mice for all
in vivo experiments in this manuscript except in Supplemental Fig. 1, where WT mice were
purchased from Taconic Farms, Inc. RAG1-/- mice were purchased from Jackson
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Laboratories. The Cleveland Clinic Institutional Animal Care and Use Committee reviewed
and approved all animal experiments.
Cell culture and reagents
Primary MEFs were isolated from WT and Act1-/- embryos at embryonic day 14.5. HEK293
cells, and WT and Act1-/- MEFs were maintained in DMEM supplemented with 10%
(volume/volume) FBS (Hyclone), penicillin G (100mg/ml) and streptomycin (100mg/ml).
Recombinant IL-17A, IL-17F, and TNF were purchased from R&D Systems; geldanamycin
GA (G3381), 17-AAG (A8476) and PU-H71 (P0030) were from Sigma; anti-Flag (M2;
F3165) was from Sigma; antibody to phosphorylated Jnk (92516), phosphorylated IκBα
(2859), IKKi (3416) was from Cell Signaling; antibody to Hsp90 (ADI-SPA-835), HOP
(ADI-SRA-1500), p23 (ADI-SPA-670) were from Enzo Life Sciences; antibody to
phosphorylated Erk (sc-7383), anti-IkB (sc-371), anti-TRAF3 (sc-1828), anti-TRAF6
(sc-7221), anti-TRAF2 (sc-876), human anti-Act1 (sc-13112), anti-IL17RA (sc-30175),
anti-Hsp70 (SC-33575), anti-actin (sc-1615) were from Santa Cruz Biotechnology.
Immunoprecipitations and luciferase assays
Cells were lysed in lysis buffer [0.5% Triton X-100, 20 mM Hepes (pH 7.4), 150mM NaCl,
12.5mM β-glycerophosphate, 1.5mM MgCl2, 10mM NaF, 2mM dithiothreitol, 1mM sodium
orthovanadate, 2mM EGTA, 20mM aprotinin, 1mM phenylmethylsulfonyl fluoride]. Cell
extracts were incubated with 1 μg of the appropriate antibodies overnight at 4°C with 20 μl
of protein A Sepharose beads. After incubation, beads were washed four times with lysis
buffer, resolved by SDS-PAGE, and analyzed by Western blotting. NFκB luciferase reporter
assays were performed as previously described17.
Retroviral production
For infection of MEFs, viral supernatants were collected 36 hours after transfection of
Phoenix cells with 5 μg Act1, Act1 (D10N) and Act1 (T6BM) cloned into pMx-IP. For T
cell infection, viral supernatant were collected 36 hours after transfection of Phoenix cells
with 4 μg Flag-tagged Act1 and Act1 (D10N) cloned into pMSCV-IRES-GFP.
Quantitative Real-time PCR
Total RNA was extracted from MEF cells or skin with TRIzol reagent (Invitrogen)
according to the manufacturer’s instructions. Skin tissues were homogenized using an
OMNI TH tissue homogenizer (Omni International) prior to RNA extraction. The cDNA
was synthesized with random hexamers (Applied Biosystems) using M-MLV reverse
transcriptase (Promega). All skin gene-expression results are expressed as 2-ΔCt where
ΔCt=Cttarget − Ctactin.
Gel-shift assay
The probe for gel-shift assays was bought from SANTA CRUZ (sc-2505). Complementary
oligonucleotides were end-labeled with [γ-32P] ATP using polynucleotide kinase (Roche).
Approximately 20,000 c.p.m. of probe were used per assay. Cytoplasmic extracts were
prepared as described14. Binding reactions were incubated for 20 min at 25 °C in a total
volume of 20 ml containing 20 mM HEPES buffer, 10 mM KCl, pH 7.0, 0.1% (volume/
volume) Nonidet P-40, 0.5 mM dithiothreitol, 0.25 mM phenylmethanesulfonyl fluoride and
10% (volume/ volume) glycerol.
Histological analysis
Tissues were fixed with 10% formalin and processed into paraffin tissue blocks using
routine methods by AML Laboratories (Baltimore, Maryland) or embedded in OCT and
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sectioned or serially sectioned to obtain consecutive levels. Paraffin embedded sections were
stained with H&E and anti-CD3 (Abcam). Frozen sections were stained with anti-CD4 (BD
Pharmigen), anti-CD11b (BD Pharmigen), and anti-Gr1 (BD Pharmigen).
Immunohistochemistry staining for CD3 were done on paraffin-embedded sections that had
been antigen-retrieved with sodium citrate. All images were captured using a DP71 digital
camera (Olympus) attached to an Olympus BX41 microscope.
Intracellular staining for IL-17+ and IL-22+ cells
Single cell suspensions were obtained from the lymph nodes or the spleen of mice and
cultured for 5 hours with PMA (20ng/ml) plus ionomycin (500ng/ml). GolgiStop (BD
Biosciences) was added during the last two hours of incubation. Following stimulation, cells
were washed and fixed with 2% PFA followed by cell permeabilization (Permeabilization
Buffer, eBiosciences). Cells were stained with anti-CD3 PerCP (BD Biosciences), anti-CD4
FITC (BD Biosciences), anti-IL-17A APC (BioLegend), and anti-IL-22 PE (eBiosciences)
and analyzed by FACSCalibur.
IL-22 neutralization in vivo
Anti-IL-22 neutralization antibodies (clone 8E11) were in-house generated by Genetech.
Starting at 21 days of age, mice were injected intraperitoneally with 500ug of anti-IL-22
antibodies in a volume of 200uL every other day until 6 weeks of age.
Isolation of skin infiltrates and cytokine detection
Skin tissue removed from animals were weighed and incubated in 2U/ml of dispase
overnight at 4°C. The epidermis was subsequently peeled from the dermis and incubated in
complete RPMI medium. The dermis was minced and incubated in complete RPMI media.
Following incubation at 37°C overnight, cells were collected by centrifugation and cultured
on anti-CD3 (3μg/ml) and anti-CD28 (3μg/ml)-coated plates. Following 12 hours of culture,
the supernatant was collected for ELISA to determine cytokine production. Cytokine
concentrations were standardized to tissue weight. IL-17A ELISA kit was purchased from
BioLegend. All other ELISA kits were purchased from R&D.
T cell polarization and retroviral transduction
Naïve CD4+ T cells were isolated from the spleen and lymph nodes of mice using Miltenyi
CD4+CD62L+ isolation kit and cultured for 3 days on plate bound anti-CD3 (3μg/ml) and
anti-CD28 (3μg/ml) under TH0 (anti-IL-4 and anti-IFN-γ) or TH17-skewing (IL-6, TGF-β,
anti-IL-4, and anti-IFN-γ) conditions. Anti-IL-4 (1μg/ml), anti-IFN-γ (2μg/ml), IL-6 (20ng/
ml), and TGF-β (0.1ng/ml). For retroviral transduction, naïve CD4+ T cells were isolated as
above and activated for 24hrs on plate-bound anti-CD3 (1μg/ml) and anti-CD28 (2μg/ml).
Following activation, cells were collected, resuspended in retroviral supernatant with 8μg/
ml polybrene, and spun at 2500rpm for 90mins at 20°C. Fresh media containing IL-6 (20ng/
ml) and TGF-β (0.1ng/ml) (TH17-skewing condition) or IL-2 (20ng/ml) were added to the
cells and incubated at 37°C. Cells were collected at 48hrs after transduction and sorted for
GFP+ cells. For adoptive transfer of transduced T cell into RAG1-/- mice, T cells were
transduced as above with IL-2. 48hrs after transduction, cells were sorted for GFP and
injected into mice at 5×106 cells per mouse.
Intranasal instillation of IL-17
Mice were anesthetized with isoflurane. Carrier-free recombinant mouse IL-17 (R&D
Systems) resuspended in sterile saline (0.9%) was instilled into the nasal opening in an
aliquot of 50μl (1μg) per mouse.
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BAL fluid and tissue collection
HL-1 medium (0.7 ml; BioWhittaker) was used to obtain BAL fluid through the trachea with
a blunt needle and 1-ml syringe. Cytospin slide preparations where obtained with Shandon
CytoSpin III Cytocentrifuge (Shandon–Thermo Scientific). Lungs were collected and then
immediately ‘snap-frozen’ in liquid nitrogen. Total RNA was obtained with TRIzol
(Invitrogen) and an OMNI TH tissue homogenizer (Omni International).
Statistical analysis
The significance of differences between two groups was determined by Student’s t-test
(Two-tailed). Unless otherwise specified, all results are shown as mean and the standard
error of the mean (mean±SEM). A p value <0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Act1 is a client protein of HSP90
(a) Lysates from MEFs treated with IL-17 (50ng/ml) for the indicated times were
immunoprecipitated with anti-Act1 or IgG control, followed by immunoblot analysis for
Hsp90, IKKi and Act1. Immunoprecipitated (IP) products are shown on left, whole cell
lysates (WCL) are shown on right. (b) MEFs were treated with Hsp90 inhibitors 17-AAG
(1μM) or PU-H71 (1μM) for the indicated times. Actin is used as loading control. The
relative amount of total Act1 to actin was quantified by densitometry. The Act1 to actin ratio
in untreated MEFs was defined as 1. (c) DMSO (control) or GA pretreated MEFs were
incubated with 10 μg/ml cycloheximide (CHX) for the indicated times. The relative amount
of total Act1 to actin was quantified by densitometry. The Act1 to actin ratio prior to CHX
treatment was defined as 1. (d) MEFs were treated with DMSO, PU-H71 (0.5μM) alone,
MG-132 (1μM) alone, or PU-H71 (0.5μM) plus MG-132 (1μM) for 12 hours. The relative
amount of total Act1 to actin was quantified by densitometry. The Act1 to actin ratio in
DMSO-treated MEFs was defined as 1. (e) Lysates from MEFs treated with PU-H71 (1μM)
for the indicated times were immunoprecipitated with anti-Act1 or IgG control. The data are
representative of three independent experiments.
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Figure 2. Hsp90 activity is required for IL-17-induced Act1-mediated signaling
MEFs pretreated with 17-AAG (a) or PU-H71 (b) for 1 hour were stimulated with IL-17
(50ng/ml) for the indicated times, followed by immunoblot analysis for phosphorylated (p-)
IκBα, p-Erk, p-Jnk, and Act1. Arrow indicates Act1 modification. (c) MEFs pretreated with
PU-H71 for 1 hour were stimulated with IL-17 (50ng/ml) for the indicated times, followed
by quantitative RT-PCR analysis for Il6, Cxcl1 and Csf2 expression. Results are presented
as fold induction relative to time 0. (d) MEFs pretreated with PU-H71 for 1 hour were
stimulated with IL-17F (50ng/ml) for the indicated times, followed by RT-PCR analysis of
Il6, Cxcl1 and Csf2 expression. Results are presented as fold induction relative to time 0. (e)
MEFs pretreated with PU-H71 for 1 hour were stimulated with IL-17 (50ng/ml) for the
indicated times. Lysates were then immunoprecipitated with anti-Act1, followed by
immunoblot analysis for Hsp90, TRAF6, TRAF3, TRAF2, IKKi and Act1.
Immunoprecipitated (IP) products are shown on left, whole cell lysates (WCL) are shown on
right. *p < 0.05, **p < 0.01 (Student’s t-test). The data are representative of three
independent experiments.
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Figure 3. Loss of interaction of psoriasis-associated variant, Act1 (D10N), with Hsp90
(a) HEK293 cells were transiently transfected with vector, Flag-tagged human wild-type
(WT) Act1, or Flag-tagged deletion mutants of human Act1: Act1Δ1-50, Act1Δ50-100,
Act1Δ100-130, Act1Δ130-155, Act1Δ155-190, Act1Δ190-300, Act1Δ300-350,
Act1Δ350-375, or Act1Δ375-420. Lysates were immunoprecipitated with anti-Flag,
followed by immunoblot analysis for Hsp90 and Flag. (b) Schematics of Act1-deletion
mutants. Right column indicates interaction with Hsp90. (c) Alignment of Act1 sequences
from Homo sapiens (human), Bos taurus (cow), Cricetulus griseus (bacteria), Mus musculus
(mouse), and Rattus norvegious (rat). Asterisks (*) denote identical amino acids and the
number sign (#) denotes conserved substitutions. (d) HEK293 cells were transfected with
vector, Flag-tagged human Act1 (WT) and Act1 (D10N). Cell lysates were
immunoprecipitated with anti-Flag, followed by immunoblot analysis for Hsp90 and Flag.
Immunoprecipitated (IP) products are shown on left, whole cell lysates (WCL) are shown on
right. The data are representative of three independent experiments (a, d).
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Figure 4. IL-17-induced Act1-Hsp90 interaction is TRAF6 independent
(a) Schematics of TRAF-binding site mutant (TB12) of Act1. (b) Act1-/- MEFs transduced
with Act1 (WT) or Act1 (TB12) were treated with IL-17 (50ng/ml) for the indicated times.
Cell lysates were immunoprecipitated with anti-Act1, followed by immunoblot analysis for
TRAF6, TRAF2, TRAF3, Hsp90, IKKi and Act1. (c) Lysates from WT or Traf6-/- MEFs
treated with IL-17 (50ng/ml) for the indicated times were immunoprecipitated with anti-
Act1, followed by immunoblot analysis for Hsp90 and Act1. (d) Act1-/- MEFs transduced
with Act1 (WT), Act1 (D10N), or Act1 (TB12) were left untreated (0) or treated with
varying concentrations of PU-H71 for 24 hours. The relative amount of total Act1 to actin
was quantified by densitometry. The Act1 to actin ratio in untreated MEFs was defined as 1.
(e) Act1-/- MEFs transduced as in (d) were treated for the indicated times with IL-17 (50ng/
ml). Cell lysates were immunoprecipitated with anti-Act1, followed by immunoblot analysis
for Hsp90, p23, HOP, Hsp70 and Act1. (f) Act1-/- MEFs transduced as in (d) were treated
for the indicated times with PU-H71 (1μM). Cell lysates were immunoprecipitated with
anti-Act1, followed by immunoblot analysis for Hsp90, p23, HOP, Hsp70 and Act1.
Immunoprecipitated (IP) products are shown on left, whole cell lysates (WCL) are shown on
right. Data are representative of three independent experiments.
Wang et al. Page 18
Nat Immunol. Author manuscript; available in PMC 2013 July 01.
$watermark-text
$watermark-text
$watermark-text
Figure 5. Act1 (D10N) is a loss of function variant
(a) Act1-/- MEFs transduced with vector, Act1 (WT), or Act1 (D10N) were subjected to
immunoblot analysis for Act1 expression. (b) Act1-/- MEFs transduced as in (a) were treated
with IL-17 (50ng/ml) for the indicated times. Cell lysates were subjected to gel-shift assay
for NF-κB activation. (c) HEK293 cells transfected with E-selectin–luciferase reporter
(100ng) and the indicated amounts of human Act1 or human Act1 (D10N) DNA, followed
by luciferase assay analysis of NF-κB activity. (d) Act1-/- MEFs transduced as in (a) were
treated with IL-17 (50ng/ml) for the indicated times, followed by immunoblot analysis.
Arrow indicates Act1-modification. (e) Act1-/- MEFs transduced as in (a) were treated with
IL-17 (50ng/ml) for the indicated times. Cell lysates were immunoprecipitated with anti-
Act1, followed by immunoblot analysis for IL-17R, TRAF6, TRAF3, TRAF2, IKKi and
Act1. Immunoprecipitated (IP) products are shown on left, whole cell lysates (WCL) are
shown on right. (f) Act1-/- MEFs transduced with vector, Act1 (WT), Act1 (TB12), or Act1
(D10N) were left untreated or treated for 3 hours with TNF (10ng/ml), IL-17A (50ng/ml),
IL-17F (50ng/ml), or TNF in combination with IL-17A, followed by RT-PCR analysis for
Il6, Cxcl1 and Csf2 expression. The data are shown as fold induction over untreated (UT).
*p < 0.05, **p < 0.01 and ***p < 0.005 (Student’s t-test). Data are representative of three
independent experiments.
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Figure 6. IL-22 neutralization attenuates skin inflammation in Act1-/- mice
(a) Skin sections from 6 weeks old Act1 (WT) or Act1-/- mice were stained with
hematoxylin and eosin (H&E) or with antibodies against cell surface markers for T cells
(CD3, CD4), macrophages (CD11b), or neutrophils (Gr-1). CD3+, CD11b+, Gr-1+ and
CD4+ cells are stained brown. Scale bar indicates 50μm. (b) Cells isolated from the spleen
and lymph nodes (cervical, axillary, and inguinal) of 6 weeks old WT or Act1-/- mice were
stimulated with PMA (20ng/ml) plus ionomycin (500ng/ml) for 5 hours followed by
intracellular staining for IL-17A and IL-22. Flow plots are gated on CD4+ T cells. Right
graphs indicate the percentage of IL-17+ and IL-22+ CD4+ T cells in the spleen and lymph
nodes. (c) Cytokine production from skin infiltrates detected by ELISA. Skin infiltrates were
isolated from the skin as described and cultured with anti-CD3/anti-CD28 for 12 hours.
Cytokine production was normalized to skin tissue weight. (d) RT-PCR analysis of cytokine
transcripts in the skin of 6 weeks old WT or Act1-/- mice. Data are graphed as mean 2-ΔCt ±
SEM, where ΔCt=Cttarget – Ctactin. (e) Act1-/- mice were treated with 500μg of anti-IL-22
(I.P. injection) every other day for 3 weeks starting at 21 days of age. Skin sections from
anti-IL-22 or isotype-treated mice were stained with hematoxylin and eosin or with anti-
CD3, anti-CD4, or anti-CD11b. Scale bar indicates 50μm. (f) RT-PCR analysis of cytokine
transcripts in the skin of anti-IL-22 or isotype treated mice. Data are graphed as mean 2-ΔCt
± SEM. *p < 0.05, **p < 0.01, ***p < 0.005, NS (not significant) (Student’s t-test). Data are
representative of three independent experiments with 3-5 mice per group per experiment.
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Figure 7. Skin inflammation is attenuated in Act1-/- Il23r-/-mice
(a) Cells isolated from the lymph nodes of 6 weeks old WT, Act1-/-, Il23r-/-, or Act1-/-
Il23r-/- mice were stimulated with PMA (20ng/ml) plus ionomycin (500ng/ml) for 5 hours
followed by intracellular staining for IL-17A and IL-22. Right graph indicates the
percentage of IL-17+ and IL-22+ CD4+ T cells in the lymph nodes. Flow plots are gated on
CD4+ T cells. (b) Skin sections from 6 weeks old WT, Act1-/-, Il23r-/-, or Act1-/- Il23r-/-
mice were stained with hematoxylin and eosin or with anti-CD3. Scale bar indicates 50μm.
(c) RT-PCR analysis of cytokine transcripts in the skin of 6 weeks old WT, Act1-/-, Il23r-/-,
or Act1-/- Il23r-/- mice. Data are graphed as mean 2-ΔCt ± SEM. *p < 0.05, **p < 0.01
(Student’s t-test). Data are representative of two independent experiments with 4 mice per
group per experiment.
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Figure 8. Skin inflammation is observed in T cell-specific Act1-/- mice
(a) Skin sections from Lck-Cre+ Act1fl/+ and Lck-Cre+ Act1fl/- mice were stained with H&E
or antibodies against cell surface markers. CD4+, CD11b+ and CD8+ cells are stained
brown. Scale bar indicates 50μm. (b) Cytokine production by skin infiltrates from Lck-Cre+
Act1fl/+ and Lck-Cre+ Act1fl/- mice. Cytokine production was normalized to tissue weight.
(c) Naïve T cells were isolated from Lck-Cre+ Act1fl/- or Lck-Cre+ Act1fl/- mice and
cultured on plate-bound anti-CD3/anti-CD28 under TH0 or TH17 skewing conditions.
Following 3 days of culture, cells were restimulated with PMA (20ng/ml) and ionomycin
(500ng/ml) for 5 hours followed by intracellular staining for IL-17A. (d) Ex vivo polarized
TH17 cells were subjected to RT-PCR analysis for Il17a and Il22 expression after 3 days of
culture (top). Culture supernatants were subjected to ELISA for IL-17A and IL-22
production (bottom). (e) Act1-/- T cells were transduced with retrovirus carrying vector, WT,
or Act1 (D10N) and polarized to TH17 cells with anti-CD3/anti-CD28 in the presence of
TGF-β and IL-6. GFP+ cells were sorted for RT-PCR analysis for Il17a and Il22 expression.
The data are shown as fold induction of polarized TH17 cells over non-polarized T cells. (f-
g) Act1-/- T cells were transduced with retrovirus carrying vector, WT, or Act1 (D10N).
GFP+ cells were sorted and injected intravenously into RAG1-/- mice at 5×106 cells per
mouse. Two weeks post adoptive transfer, lymph nodes (f) and spleen (g) were isolated from
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RAG1-/- mice, followed by RT-PCR analysis for Il17a and Il22 expression. *p < 0.05, **p <
0.01, ***p < 0.005, NS (not significant) (Student’s t-test). Data are representative of three
(a-c) or two (d-g) independent experiments.
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